- Home
- CRVS vs TBLD Comparison
CRVS vs TBLD Comparison
Compare CRVS & TBLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- TBLD
- Stock Information
- Founded
- CRVS 2014
- TBLD 2021
- Country
- CRVS United States
- TBLD United States
- Employees
- CRVS N/A
- TBLD N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- TBLD Investment Managers
- Sector
- CRVS Health Care
- TBLD Finance
- Exchange
- CRVS Nasdaq
- TBLD Nasdaq
- Market Cap
- CRVS 516.0M
- TBLD 530.3M
- IPO Year
- CRVS 2016
- TBLD N/A
- Fundamental
- Price
- CRVS $5.22
- TBLD $17.04
- Analyst Decision
- CRVS Strong Buy
- TBLD
- Analyst Count
- CRVS 5
- TBLD 0
- Target Price
- CRVS $12.38
- TBLD N/A
- AVG Volume (30 Days)
- CRVS 1.6M
- TBLD 99.9K
- Earning Date
- CRVS 11-12-2024
- TBLD 01-01-0001
- Dividend Yield
- CRVS N/A
- TBLD 7.85%
- EPS Growth
- CRVS N/A
- TBLD N/A
- EPS
- CRVS N/A
- TBLD N/A
- Revenue
- CRVS N/A
- TBLD N/A
- Revenue This Year
- CRVS N/A
- TBLD N/A
- Revenue Next Year
- CRVS N/A
- TBLD N/A
- P/E Ratio
- CRVS N/A
- TBLD N/A
- Revenue Growth
- CRVS N/A
- TBLD N/A
- 52 Week Low
- CRVS $1.30
- TBLD $13.44
- 52 Week High
- CRVS $10.00
- TBLD $16.26
- Technical
- Relative Strength Index (RSI)
- CRVS 41.23
- TBLD 67.14
- Support Level
- CRVS $4.60
- TBLD $16.19
- Resistance Level
- CRVS $6.47
- TBLD $16.50
- Average True Range (ATR)
- CRVS 0.39
- TBLD 0.24
- MACD
- CRVS 0.06
- TBLD 0.09
- Stochastic Oscillator
- CRVS 33.16
- TBLD 86.73
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About TBLD Thornburg Income Builder Opportunities Trust
Thornburg Income Builder Opportunities Trust is a diversified, closed-end management investment company. The Trust's investment objective is to provide current income. The Trust will seek to achieve its investment objective by investing, directly or indirectly, at least 80% of its Managed Assets.